Systemic immunologic effects of long-term dupilumab treatment in severe eosinophilic asthma beyond clinical outcomes
{{output}}
Introduction: Dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling, is used in severe eosinophilic asthma to improve clinical control and suppress type 2 inflammation. ... ...
